Last reviewed · How we verify

Evrenzo — Competitive Intelligence Brief

Evrenzo (ROXADUSTAT) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Hematology.

marketed Thyroid hormone receptor beta Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Evrenzo (ROXADUSTAT) — Astellas Pharma Europe B.V..

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Evrenzo TARGET ROXADUSTAT Astellas Pharma Europe B.V. marketed Thyroid hormone receptor beta 2021-01-01
Unithroid LEVOTHYROXINE SODIUM Fresenius Kabi marketed l-Thyroxine Thyroid hormone receptor beta 2000-01-01
LT3 (liothyronine) LT3 (liothyronine) M. Medici phase 3 Thyroid hormone replacement Thyroid hormone receptor alpha (TRα), Thyroid hormone receptor beta (TRβ)
MGL-3196 MGL-3196 Madrigal Pharmaceuticals, Inc. phase 3 Thyroid hormone receptor beta (THR-β) selective agonist THR-β (thyroid hormone receptor beta)
Veligrotug (VRDN-001) Veligrotug (VRDN-001) Viridian Therapeutics, Inc. phase 3 Thyroid hormone receptor beta (THR-β) agonist Thyroid hormone receptor beta (THR-β)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Evrenzo — Competitive Intelligence Brief. https://druglandscape.com/ci/roxadustat. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: